Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...

Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...

When smart people make irrational choices, we often assume they are acting out of selfishness, stupidity or stubbornness.

From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...

The FDA gave Aduhelm an accelerated approval, meaning that Biogen has to carry out a post-marketing trial to confirm that it is effective, but critics say results from that will be years away.

A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...

In 2022, the Medicare Part B standard premium will increase from $148.50 to $170.10. This $21.60 increase (14.5%) is the largest since the Medicare program began in 1965 and much higher than was ...

Philadelphia-based Independence Blue Cross has set a benefit exclusion for products that receive accelerated approval from ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...